Jpmorgan Chase & CO Avadel Pharmaceuticals PLC Transaction History

Jpmorgan Chase & CO

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$12.55 - $17.22 $62,975 - $86,409	5,018 Added 10.41%	53,221 $898,000
Q4 2023 Feb 12, 2024	SELL	$9.64 - $14.59 $3.9 Million - $5.9 Million	-404,269 Reduced 89.35%	48,203 $680,000
Q3 2023 Nov 14, 2023	BUY	$10.3 - $15.99 $1.23 Million - $1.92 Million	119,848 Added 36.03%	452,472 $4.66 Million
Q2 2023 Aug 11, 2023	SELL	$8.48 - $16.48 $214,001 - $415,889	-25,236 Reduced 7.05%	332,624 $5.48 Million
Q1 2023 May 11, 2023	BUY	$6.41 - $9.95 $2.14 Million - $3.32 Million	333,397 Added 1362.86%	357,860 $3.28 Million
Q4 2022 Feb 13, 2023	SELL	$5.02 - $10.0 $11,992 - $23,890	-2,389 Reduced 8.9%	24,463 $176,000
Q3 2022 Nov 14, 2022	BUY	$2.57 - $7.31 $5,122 - $14,568	1,993 Added 8.02%	26,852 $135,000
Q2 2022 Aug 11, 2022	SELL	$1.07 - $6.95 $5,094 - $33,088	-4,761 Reduced 16.07%	24,859 $60,000
Q1 2022 May 11, 2022	BUY	$5.46 - $8.29 $9,598 - $14,573	1,758 Added 6.31%	29,620 $202,000
Q4 2021 Feb 10, 2022	SELL	$7.34 - $11.18 $1.62 Million - $2.47 Million	-220,602 Reduced 88.79%	27,862 $225,000
Q3 2021 Nov 12, 2021	BUY	$6.49 - $9.91 $1.61 Million - $2.46 Million	248,464 New	248,464 $2.43 Million

1.07M

Ticker AVDL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 60,581,300
Market Cap $661M
Description
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.